Premier Biomedical Inc (BIEI)

[Ricopai]

I have not seen this 03/24/20 PR here on the board and thought it might be of interest.

Press Release

How Premier Biomedical Can Quickly Grow into Two Multi-Billion Dollar Markets Treating Covid-19 & Opioid Addiction
Published: March 24, 2020 at 10:30 a.m. ET

Mar 24, 2020 (Market News Bizz via Comtex) -- Premier Biomedical, Inc. (BIEI) is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents.

On March 23, 2020, the company announced the filing of a provisional patent application, Method for Treating and Curing Covid-19 Infection. Through its exclusive global patent license agreement, Premier Biomedical will have exclusive rights to practice the invention.

The patent application involves the removal of disease-specific antigens via an extracorporeal process. These antigens are associated with the ability of Covid-19 to replicate. By targeting these disease antigens with a complexing agent and causing them to bind together, the resulting molecular compound can then be removed in a brief clinical process.

Dr. Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. stated, "We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as "cytokine storm", via the removal of certain non-structural proteins which the Covid-19 virus needs for replication."

This is a big step forward for the company and can strengthen their enterprise value in a very small but growing Covid-19 treatment space with a total addressable market that may reach several billion dollars just this year alone.

What’s the potential market size?

Calculating the total market size for a possible COVID-19 treatment isn’t that easy, especially since the total market size is determined by just how much the virus spreads. In less than two weeks, countries like Italy have seen the number of confirmed cases multiply by over a dozen times.

Currently, there are more than 380,000 confirmed cases and over 16,500 deaths due to this spreading virus. Some of the regional territories that seemed to have had things under control have quickly spiraled into a dangerous epidemic in less time than one thought was possible. Just look at New York City.

Some analysts, such as Geoff Meacham of Bank of America Merrill Lynch, said in February that the total upside for remdesivir isn’t that impressive and won’t do much to change Gilead’s long-term financial outlook. He predicted that total COVID-19-related remdesivir sales would reach a one-time figure of just $2.5 billion USD.

If you were to look at just the worst-hit parts affected in mainland China, there are around 11.1 million people in the city of Wuhan and approximately 61.9 million living in the Hubei province. If just half of the province’s population, about 30 million, take Remdesivir on a preventative basis, Gilead would earn a lot of revenue.

Using that situation as an example, the total addressable market in just the Hubei province would be worth $7.8 billion, if assuming the previous $260 price target for the drug. In comparison, Gilead’s Q4 2019 revenue came in at about $5.8 billion. Gilead would have a hard time supplying that many treatments of Remdesivir at first, but that just goes to show just how much money the drug could make if everything goes right.

Yet, there is opportunity for other companies to accrue even a small market share in this space, like Premier. Factoring Premier Biomedical's relationships with rehab centers, government agencies (think national guard deployments in the US) at both state and federal levels, they would have near immediate distribution lines to those in need.

In any case, these relationships can quickly result in millions to tens of millions of earned revenue from drug sales and/or licensing agreements.

Aside from a promising revenue growth opportunity in the Covid-19 treatment space, Premier Biomedical is well-positioned to expand into the Addiction Treatment market with a very promising anti-addiction patch!

Opioid addiction is a national epidemic affecting millions of people around the world.

How Big is the Opioid Addiction Treatment Market?

The global opioid use disorder market size is expected to reach $4.5 billion USD by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10.1% over the forecast period. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth.

In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

In July 2019, the company announced the signing of a joint venture with New Earth Development Corporation, RushNet, Inc., and XYZ Hemp, Inc. to manufacture, market and sell a revolutionary Anti-Addiction Patch containing Premier Biomedical's patented natural and synthetic formulation. The product will be based on the topical pain relieving patch technology currently marketed by Premier Biomedical. Because of the current focus on the opioid drug overdose epidemic, not only in the United States, but worldwide, the joint venture will quickly seek to expand sales globally.

Dr. Mitchell Felder, Chairman of the Board of Premier Biomedical, stated, "The Anti-Addiction Patch is a proprietary blend of natural components, including hemp oil extracts and a patented combination (US Pat. # 8865733) of Naltrexone and Cyclobenzaprine, two long-time FDA approved drugs. These medications are extremely well documented in the prevention and treatment of narcotic addiction.

"This is believed to be a revolutionary and efficacious treatment for opioid addiction. We anticipate no negative side-effects due to its intended topical delivery system, yet it would allow for both the outpatient and inpatient treatment. The topical patch is designed to provide a steady release of Naltrexone with an increased penetration and bioavailability of the product via a proprietary blend of components and the topical delivery system. The blend of hemp oil extracts along with Naltrexone and Cyclobenzaprine is expected to eliminate a desire for opioid abuse. The Anti-Addiction Patch will be prescribed to prophylactically protect a patient from an opioid-induced drug overdose, while simultaneously reducing the ability of the drug-addicted patient to achieve an opioid-induced high. Each patch is designed to provide continuous treatment for up to 7-10 days."

William A. Hartman, President and CEO of Premier Biomedical, commented, "The Anti-Addiction Patch utilizes synergistic technologies from both the Biologics and Pain Management Divisions of Premier Biomedical and is intended to alleviate the drug overdose problem which claims hundreds of victim per week in the USA alone. Initial sales efforts of the revolutionary Anti-Addiction Patch will target addiction clinics and rehab centers as well as government agencies at both the Federal and State levels. Our plan is to quickly branch out beyond the domestic market after a successful launch in the United States."

"The new group has already held a meeting with a major multi-faceted defense contractor, and interest was expressed not only in the proposed Anti-Addiction Patch, but also in Premier's treatment and potential cure for PTSD. Subsequent meetings are being scheduled with this major corporation as well as others to develop and exploit these promising technologies."

Premier Biomedical has a very experienced team and advisory board. They seem to have been very busy the past several months and are now better positioned to pounce on massive market opportunities in the Covid-19 and Addiction treatment multi-billion markets.

Premier currently has a market cap under $1M and seems fairly undervalued when considering the patents they own, list of licensing partners, expansive distribution channels, along with treatments for two multi-billion industries that are only growing in size.

For more information about Premier Biomedical, Inc. you can visit them here: http://www.premierbiomedical.com and http://www.painreliefmeds.com

There are certain statements and opinions contained herein that may contain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution any and all investors that there may be forward-looking statements and that these statements make no guarantee of future performance. The statements herein consist of opinions and assumptions as of the date of this article and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what you might expect. Forward-looking statements in this article are opinions and apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Actual results could differ materially from current projections or implied.

https://www.marketwatch.com/press-release/how-premier-biomedical-can-quickly-grow-into-two-multi-billion-dollar-markets-treating-covid-19-opioid-addiction-2020-03-24